Login
$JBIO
$15.34 -$0.80 (4.99%) Live

$JBIO SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026

28 Oct 2026 SCHEDULE 13G
27 Oct 2026 SCHEDULE 13G
30 Sep 2026 8-K: Other Events

On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating ...

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

17 Jul 2026 SCHEDULE 13G
08 Jul 2026 SCHEDULE 13G/A
01 Jul 2026 8-K: Entry into a Material Definitive Agreement

On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon Therapeutics, Inc. (“Paragon”), pursuant to which Paragon granted the Company a royalty-bearing, wor...

26 Jun 2026 Form 4: Eisner Mark, Director

Granted 47,675 Stock Option (Right to Buy)

26 Jun 2026 Form 3: Eisner Mark, Director

No securities owned

26 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

San Francisco and Vancouver, British Columbia, June 26, 2026 — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases,...

11 Jun 2026 Form 4: Cain Christopher W., Director

Granted 34,843 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Dobmeier Eric, Director

Granted 34,843 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Klein Lawrence Otto, Director

Granted 34,843 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Lavelle Erin, Director

Granted 34,843 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Fairmount Funds Management Llc, Director and 4 others

Granted 34,843 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support